Skip to search formSkip to main contentSkip to account menu

dehydroxymethylepoxyquinomicin

Known as: DHMEQ cpd 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Dehydroxymethylepoxyquinomicin (DHMEQ) is a low-m.w. compound that strongly inhibits NF-κB. Previous reports showed that DHMEQ… 
2011
2011
Dehydroxymethylepoxyquinomicin (DHMEQ, 1a) is a specific and potent inhibitor of NF-κB, and it is now being developed as an anti… 
2007
2007
A new NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), inhibited proliferation and induced apoptosis in human Burkitt… 
2006
2006
Background. Nuclear factor (NF)-&kgr;B plays a crucial role in lymphocyte activation, proliferation, and survival. We examined… 
Review
2006
Review
2006
Adult T-cell leukemia/lymphoma (ATL), a fatal T-cell leukemia/lymphoma resistant to chemotherapy, is caused by human T-cell… 
Highly Cited
2005
Highly Cited
2005
Adult T-cell leukemia (ATL) is an aggressive neoplasm caused by human T-cell leukemia virus type I (HTLV-I). The nuclear… 
2005
2005
Nuclear factor-kappaB (NF-kappaB) is constitutively activated in multiple myeloma cells. Several proteasome inhibitors have been… 
2005
2005
Purpose: To investigate the association between serum interleukin-6 (IL-6) and cachexia in patients with prostate cancer and the… 
2005
2005
PURPOSE To investigate the association between serum interleukin-6 (IL-6) and cachexia in patients with prostate cancer and the…